A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel
- 29 July 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 195, 107902
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- miR-324-5p Contributes to Cell Proliferation and Apoptosis in Pancreatic Cancer by Targeting KLF3Molecular Therapy-Oncolytics, 2020
- miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcomaCancer Letters, 2020
- Time trends and predictors of survival in surgically resected early‐stage non–small cell lung cancer patientsJournal of Surgical Oncology, 2020
- Circulating miRNA analysis for cancer diagnostics and therapyMolecular Aspects of Medicine, 2020
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and TreatmentMayo Clinic Proceedings, 2019
- Definitive treatment patterns and survival in stage II non-small cell lung cancerLung Cancer, 2018
- MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathwayGene, 2018
- Serum MicroRNA‐150 Predicts Prognosis for Early‐Stage Non‐Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1Clinical Pharmacology & Therapeutics, 2017
- The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung CancersThe Annals of Thoracic Surgery, 2013
- Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patientsLung Cancer, 2013